secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001171843-24-000113
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus provides 2024 outlook: $132M cash, reduced burn, multiple Phase 2a readouts expected in 1H 2024
--------------------------------------------------------------------------------

- Cash, equivalents and investments ~$132M at Dec 31, 2023; net burn expected $63-67M in 2024 vs ~$85M in 2023.
- Cash runway extends into Q1 2026.
- End-of-treatment data from imdusiran Phase 2a trials AB-729-201 and AB-729-202 expected 1H 2024.
- Third Phase 2a imdusiran trial (AB-729-203, with durvalumab) to begin in 1H 2024; AB-101 Phase 1a/1b data also expected 1H 2024.
- Moderna LNP claim construction hearing set Feb 8, 2024; trial expected 1H 2025. Pfizer/BioNTech lawsuit ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324000113/0001171843-24-000113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324000113/f8k_010624.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-000113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer